Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Impact of Vitamin a Supplementation on Disease Progression in Patients With Multiple Sclerosis Pubmed



Bitarafan S1 ; Sabooryaraghi A2 ; Sahraian MA3 ; Nafissi S4 ; Togha M5 ; Moghadam NB6 ; Roostaei T3 ; Siassi F7 ; Eshraghian MR8 ; Ghanaati H9 ; Jafarirad S10, 11 ; Rafiei B9 ; Harirchian MH1
Authors
Show Affiliations
Authors Affiliations
  1. 1. Iranian Center of Neurological Research, Neuroscience Institute, Imam Khomeini Hospital, Tehran University of Medical Sciences, Tehran, Iran
  2. 2. Department of Molecular and Cellular Nutrition, School of Nutrition and Dietetics, Tehran University of Medical Sciences, Tehran, Iran
  3. 3. Sina MS Research Center, Neuroscience Institute, Tehran University of Medical Sciences, Tehran, Iran
  4. 4. Department of Neurology, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran
  5. 5. Department of Neurology, Sina Hospital, Tehran University of Medical Sciences, Tehran, Iran
  6. 6. Department of Neurology, Imam Hossein Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran
  7. 7. Department of Community Nutrition, School of Nutrition and Dietetics, Tehran University of Medical Sciences, Tehran, Iran
  8. 8. Department of Biostatistics, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran
  9. 9. Advanced Diagnostic and Interventional Radiology Research Center, Medical Imaging Center, Imam Khomeini Hospital, Tehran, Iran
  10. 10. Nutrition and metabolic disease research center, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran
  11. 11. Department of Nutrition, School of Paramedicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran

Source: Archives of Iranian Medicine Published:2015


Abstract

Background: Many studies have shown that active vitamin A derivatives suppress the formation of pathogenic T cells in multiple sclerosis (MS) patients. The aim of the present study is to determine theimpact of vitamin A on disease progression in MS patients. Methods: A total of 101 relapsing-remitting MS (RRMS) patients were enrolled in a 1-yrplacebo-controlled randomized clinical trial.The treated group received 25000IU/d retinyl palmitate for six months followed by 10000IU/d retinyl palmitate for another six months. The results ofthe expanded disability status scale (EDSS) and multiple sclerosis functional composite (MSFC) were recorded at the beginning and the end of the study. The relapse rate was recorded during the intervention. Patients underwent baseline and follow-up brain MRIs. Results: The results showed Mean ± SD of MSFC changes in the treated group was (-0.14 ± 0.20) and in the placebo group was (-0.31 ± 0.19). MSFC was improved significantly (p< 0.001) in the treatment group. There were no significant differences between the Mean ± SD ofEDSS changes in thet-reated (0.07 ± 0.23) and the placebo (0.08 ± 0.23) groups (p = 0.73). There were also no significant differences between the Mean ± SD of annualized relapse rate in the treated group (-0.36 ± 0.56) and placebo (-0.53 ± 0.55) groups (p = 0.20). The Mean ± SD of enhanced lesions in the treatment (0.4 ± 1.0) and in the placebo (0.2 ± 0.6) groups were not significantly different (p = 0.26). Volume of T2 hyperintense lesions Mean ± SD was not significantly different between treatment (45 ± 137) and placebo (23 ± 112) groups after intervention (p = 0.23). Conclusion: Vitamin A improved total MSFC score in RRMS patients, but it did not change EDSS, relapse rate and brain active lesions. © 2015, Academy of Medical Sciences of I.R. Iran. All rights reserved.
Other Related Docs
19. A New Linearly Constrained Minimum Variance Beamformer for Reconstructing Eeg Sparse Sources, International Journal of Imaging Systems and Technology (2019)